SRP273719 |
Immunopathogenesis of hidradenitis suppurativa and response to anti–TNF-α therapy |
42 samples (HS skin lesion pre-TNF = 19: HS skin lesion mild-moderate HS = 7: healthy skin control = 16) |
Highly enriched pathways in HS lesioned skin are immune related. Signatures of complement activation, B cell signaling, and pathways involving phagocytosis were found to be unique to HS. TNF-α–regulated genes, IFN-γ, and IL-1β were selected as the major drivers of the inflammatory pathways in HS skin lesions. Nonetheless, IL-1 receptor antagonist, IL-1RN, and IL-10RA, 2 potent immunoregulatory molecules, were relatively reduced in HS skin. Alongside, α-catenin and sirtuin 1, both important for regulation of cell proliferation and survival, were reduced in HS skin. |
SRP272659 |
Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis |
32 samples (HS skin lesion = 22: healthy skin control = 10) |
Several upregulated genes in the skin were associated with B cell responses, including immunoglobulin genes such as IGLV3-27, CD19, and CD79a. Other important genes found were the antimicrobial gene DEFB4A; CXCL13, a B cell chemoattractant, and the neutrophil chemokine CXCL1. In summary, they found B cells, and in particular plasma cells, as a potential therapeutic target in HS. |
SRP168930 |
The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction |
7 samples (HS skin lesion = 3: healthy skin control = 4) |
IL-1β is highly active in HS, contributing to local and systemic inflammation. IL-1β induces expression of many molecules involved in extracellular matrix destruction including MMPs, ADAM12, serpinA1, COL3A1, and COL10A1, and immune cell infiltration such as CXCL1, CXCL6, CCL7, CXCL10, CXCL16, CXCL13, CCL24, CCL2, CCL8, and CCL20. IL-1β and, therefore, MMP1, MMP3, MMP9, MMP10, CCL2, CXCL1, IL-6, and IL-32 were upregulated when compared with healthy control skin and psoriasis lesions. |